Trial Profile
Randomized Phase II study of Bevacizumab with SOX versus Bevacizumab with XELOX as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1 and CPT-11
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
- Indications Colorectal cancer
- Focus Therapeutic Use
- 22 Dec 2011 New trial record